Market Place
Sourcing Support
Immix Bio To Join Jefferies Global Healthcare Conference
09 Apr 2026 //
GLOBENEWSWIRE
Immix Biopharma To Participate In Upcoming Investor Conferences
03 Mar 2026 //
GLOBENEWSWIRE
Immix Biopharma Closes Upsized $100M Underwritten Common Offering
09 Dec 2025 //
GLOBENEWSWIRE
Immix Bio To Present At Guggenheim Healthcare Innovation Conf
14 Oct 2025 //
GLOBENEWSWIRE
Immix Biopharma Attends FDA CEO Forum in Washington DC
06 Jun 2025 //
GLOBENEWSWIRE
Immix Biopharma Expands U.S. Sites for AL Amyloidosis Trial
23 May 2025 //
GLOBENEWSWIRE
Immix Biopharma`s NXC-201 Trial Data at ASCO 2025
23 Apr 2025 //
GLOBENEWSWIRE
Immix Biopharma to Host Investor & Media Conference Call
09 Dec 2024 //
GLOBENEWSWIRE
Immix Biopharma Presents NXC-201 Data at ASH Annual Meeting
25 Nov 2024 //
GLOBENEWSWIRE
Immix Biopharma Doses 1st Patient In U.S. AL Amyloidosis Trial
08 Jul 2024 //
GLOBENEWSWIRE
Immix Bio Announces œBe Proactive in AL AL Amyloidosis Awareness Initiative
05 Mar 2024 //
GLOBENEWSWIRE
Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock
08 Feb 2024 //
GLOBENEWSWIRE
Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock
05 Feb 2024 //
GLOBENEWSWIRE
Nexcella Announces Dr. Vaishali Sanchorawala Joins Scientific Advisory Board
04 Jan 2024 //
GLOBENEWSWIRE
Nexcella Announces Dr. Marko Radic Joins Scientific Advisory Board
18 Dec 2023 //
GLOBENEWSWIRE
Immix to Present at the 2023 JMP Securities Hematology and Oncology Summit
30 Nov 2023 //
GLOBENEWSWIRE
Immix Biopharma to Host KOL Event to Discuss its BCMA
22 Nov 2023 //
GLOBENEWSWIRE
Immix Bio Reports 2nd Positive Trial Data Readout in IMX-110 IMMINENT-01 Trial
17 Jul 2023 //
GLOBENEWSWIRE
Immix Biopharma Subsidiary Nexcella Appoints Edward J. Borkowski, former CFO
22 Jun 2023 //
GLOBENEWSWIRE
Immix Biopharma Subsidiary Nexcella Appoints Jeffrey H. Cooper, BOD
20 Jun 2023 //
GLOBENEWSWIRE
Immix Biopharma Subsidiary Nexcella Appoints Mary Sue Coleman, formerJ&J BOD
16 Jun 2023 //
GLOBENEWSWIRE
Nexcella Appoints Henry McKinnell, Jr., former Chairman & CEO of Pfizer Inc
12 Jun 2023 //
GLOBENEWSWIRE
Immix reports positive interim results from cancer combo therapy trial
04 May 2023 //
CLINICAL TRIALS ARENA
Immix Biopharma Confirms No Exposure to Silicon Valley Bank or Silvergate Bank
10 Mar 2023 //
GLOBENEWSWIRE
Immix Biopharma Doses Additional Patients in Ongoing Phase 1b/2a IMX-110 Trial
13 Jan 2023 //
GLOBENEWSWIRE
Hadassah Medical and Bar-Ilan University Collaborate with Immix BioPharma
04 Jan 2023 //
PR NEWSWIRE
Immix Biopharma Files $250 Million Mixed Shelf; Shares up After Hours
03 Jan 2023 //
FIRST WORLD PHARMA
Immix Biopharma Announces 16th Patient Dosing in Ongoing Phase 1b/2a IMX-110
20 Dec 2022 //
GLOBENEWSWIRE
ImmixBio Ships Tislelizumab for Patient Dosing in its Combination Trial
19 Dec 2022 //
GLOBENEWSWIRE
Immix Biopharma in-licenses NXC-201 Demonstrating High Response Rate
14 Dec 2022 //
GLOBENEWSWIRE
Immix Announces Patient Dosing in Ongoing Phase 1b/2a IMX-110 Monotherapy Trial
13 Dec 2022 //
GLOBENEWSWIRE
ImmixBio Releases and Ships Scaled-Up GMP Batches of IMX-110 for Clinical Trial
12 Dec 2022 //
GLOBENEWSWIRE
Immix Biopharma Receives Institutional Review Board Approval to IMX-110
11 Nov 2022 //
GLOBENEWSWIRE
Immix to Present Milestones Achieved to Enable Kick-Off of 2 IMX-110 Trials
25 Oct 2022 //
GLOBENEWSWIRE
Immix Biopharma Announces Share Repurchase Program
09 May 2022 //
GLOBENEWSWIRE
Immix Biopharma, Inc. says IMMX Milestone Day to be Held on April 5, 2022
07 Mar 2022 //
GLOBENEWSWIRE
ImmixBio Initiates IMX-110 GMP Manufacturing Scale-Up
31 Jan 2022 //
GLOBENEWSWIRE
ImmixBio Shows Positive IMX-110 Phase 1b/2a Interim Clinical Trial Safety Data
19 Jan 2022 //
GLOBENEWSWIRE
ImmixBio IMX-110 Produced 50% Positive Response Rate in First-Line-Therapy
12 Jan 2022 //
GLOBENEWSWIRE
Oncology biotech Immix Biopharma sets terms for $21 million IPO
07 Oct 2021 //
RENAISSANCECAPITAL
Oncology biotech Immix Biopharma files for a $25 million IPO
17 Sep 2021 //
RENAISSANCECAPITAL
ImmixBio Announces Dr. Jane Buchan Joins Board of Directors
28 Jul 2021 //
PRNEWSWIRE
Immix Doses First Patient in USA in its Phase 1b/2a Trial in Patients
04 Feb 2020 //
PR NEWSWIRE
Immix adds Biotech VC Mesa to Investor Syndicate and Receives IRB Approval
17 Dec 2019 //
BIO SPACE
